AR098854A1 - 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas - Google Patents
5-aril-1-imino-1-oxo-[1,2,4]tiadiazinasInfo
- Publication number
- AR098854A1 AR098854A1 ARP140104787A ARP140104787A AR098854A1 AR 098854 A1 AR098854 A1 AR 098854A1 AR P140104787 A ARP140104787 A AR P140104787A AR P140104787 A ARP140104787 A AR P140104787A AR 098854 A1 AR098854 A1 AR 098854A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- alkyl
- heteroaryl
- group
- cyano
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- -1 C1− alkyl 6 Chemical group 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente proporciona un compuesto que tiene actividad inhibidora de BACE1, su fabricación, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos son útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer. BACE es una enzima escisora de APP en sitio b. Reivindicación 1: Un compuesto de fórmula (1), en la que R¹ se selecciona entre el grupo que consiste en i) alquilo C₁₋₆, y ii) halógeno-alquilo C₁₋₆; R² se selecciona entre el grupo que consiste en i) hidrógeno, ii) halógeno; iii) -NH-C(=O)-R⁴, iv) arilo, v) arilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno, vi) heteroarilo, vii) heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre R⁶, y viii) -CºC-R⁵; R³ es halógeno; R⁴ se selecciona entre el grupo que consiste en i) heteroarilo, y ii) heteroarilo opcionalmente sustituido por 1 - 3 sustituyentes seleccionados individualmente entre R⁶; R⁵ se selecciona entre el grupo que consiste en i) arilo, ii) arilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno, iii) heteroarilo, y iv) heteroarilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, halógeno-alquilo C₁₋₆ y halógeno; R⁶ se selecciona entre el grupo que consiste en i) ciano, ii) halógeno; iii) alquilo C₁₋₆, iv) halógeno-alquilo C₁₋₆, v) alquinilo C₂₋₆-O-, vi) heteroarilo, y vii) heteroarilo, heteroarilo sustituido por 1 - 3 sustituyentes seleccionados individualmente entre ciano, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno-alquilo C₁₋₆, halógeno-alcoxi C₁₋₆ y halógeno; R⁷ se selecciona entre el grupo que consiste en i) halógeno, y ii) halógeno-alquilo C₁₋₆; m es 1 ó 2; n es 0 ó 1; y p es 0, 1 ó 2; o sales farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198700 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098854A1 true AR098854A1 (es) | 2016-06-15 |
Family
ID=49876438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104787A AR098854A1 (es) | 2013-12-20 | 2014-12-19 | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9605006B2 (es) |
| EP (1) | EP3083644B1 (es) |
| JP (1) | JP6461162B2 (es) |
| KR (1) | KR102285306B1 (es) |
| CN (2) | CN105683199B (es) |
| AR (1) | AR098854A1 (es) |
| BR (1) | BR112016007430A2 (es) |
| CA (1) | CA2924022A1 (es) |
| MX (1) | MX365292B (es) |
| RU (1) | RU2016128365A (es) |
| TW (1) | TW201609754A (es) |
| WO (1) | WO2015091595A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6543697B2 (ja) * | 2014-08-15 | 2019-07-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ２，２，２−トリフルオロエチル−チアジアジン類 |
| US10246468B2 (en) * | 2015-08-12 | 2019-04-02 | Hoffmann-La Roche Inc. | BACE1 inhibitors |
| CN114644566A (zh) * | 2020-12-21 | 2022-06-21 | 抚顺顺能化工有限公司 | 一种2-氨基-2-苯基丁酸的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2634188A4 (en) * | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| US8404680B2 (en) * | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US9067924B2 (en) * | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
| US9145426B2 (en) * | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US9221839B2 (en) * | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| BR112014004181A2 (pt) * | 2011-08-22 | 2017-06-13 | Merck Sharp & Dohme | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia |
| JP6134654B2 (ja) * | 2012-02-08 | 2017-05-24 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2968356B1 (en) * | 2013-03-15 | 2018-03-07 | Merck Sharp & Dohme Corp. | S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use |
-
2014
- 2014-12-17 RU RU2016128365A patent/RU2016128365A/ru unknown
- 2014-12-17 EP EP14821587.4A patent/EP3083644B1/en not_active Not-in-force
- 2014-12-17 JP JP2016541590A patent/JP6461162B2/ja not_active Expired - Fee Related
- 2014-12-17 WO PCT/EP2014/078133 patent/WO2015091595A1/en not_active Ceased
- 2014-12-17 KR KR1020167016040A patent/KR102285306B1/ko not_active Expired - Fee Related
- 2014-12-17 BR BR112016007430A patent/BR112016007430A2/pt not_active Application Discontinuation
- 2014-12-17 US US15/105,725 patent/US9605006B2/en not_active Expired - Fee Related
- 2014-12-17 CA CA2924022A patent/CA2924022A1/en not_active Abandoned
- 2014-12-17 CN CN201480058595.4A patent/CN105683199B/zh not_active Expired - Fee Related
- 2014-12-17 CN CN201810567706.4A patent/CN108690052A/zh active Pending
- 2014-12-17 MX MX2016006906A patent/MX365292B/es active IP Right Grant
- 2014-12-19 AR ARP140104787A patent/AR098854A1/es unknown
- 2014-12-19 TW TW103144659A patent/TW201609754A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201609754A (zh) | 2016-03-16 |
| EP3083644A1 (en) | 2016-10-26 |
| CN105683199B (zh) | 2018-06-26 |
| KR20160098263A (ko) | 2016-08-18 |
| EP3083644B1 (en) | 2019-03-13 |
| CA2924022A1 (en) | 2015-06-25 |
| RU2016128365A (ru) | 2018-01-25 |
| US20160318952A1 (en) | 2016-11-03 |
| JP6461162B2 (ja) | 2019-01-30 |
| WO2015091595A1 (en) | 2015-06-25 |
| CN105683199A (zh) | 2016-06-15 |
| JP2017500344A (ja) | 2017-01-05 |
| HK1220204A1 (zh) | 2017-04-28 |
| MX365292B (es) | 2019-05-29 |
| KR102285306B1 (ko) | 2021-08-04 |
| BR112016007430A2 (pt) | 2017-08-01 |
| MX2016006906A (es) | 2016-08-17 |
| CN108690052A (zh) | 2018-10-23 |
| US9605006B2 (en) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR095347A1 (es) | Compuestos orgánicos | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR098912A1 (es) | Inhibidores de syk | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| MX343264B (es) | Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos. | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112014013974A2 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| UY33950A (es) | Inhibidores de benzodioxano de la producciòn de leucotrieno | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| CO2017000980A2 (es) | Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |